medigraphic.com
Instituto Nacional de Salud Pública

2022, Number 3

<< Back

salud publica mex 2022; 64 (3)

Impact of the Covid-19 pandemic on breast cancer screening and how to act quickly and safely

Sollozo-Dupont I, Galván-Espinoza HA, Castillo-López JP, Benítez-López EO, Rocha-Nava SL, Villaseñor-Navarro Y

Language: Spanish
References: 21
Page: 333-339
PDF size: 303.23 Kb.


ABSTRACT

Prolonged delays in breast cancer screening related to the Covid-19 pandemic may lead to delayed diagnoses, poor health consequences, and an increase in cancer disparities among women already experiencing health inequities. There is a void in empirical high-quality evidence to support a specific strategy for administering cancer screening during a pandemic and its resolution phase, but several pragmatic considerations can help guide its recovery and ensure its continuity. One of these strategies is to address the backlogs in the diagnostic and follow-up of breast cancer, designing programs that align with the current epidemiological situation. Here, we present some approaches for the generation of breast cancer detection programs which embody recommendations and obligations to overcome the SARS-CoV-2. With this initiative, we reinforce our commitment to advance health care by ensuring more women have access to preventive care.


REFERENCES

  1. Secretaría de Gobernación, Diario Oficial de la Federación. Acuerdopor el que se declara como emergencia sanitaria por causa de fuerzamayor, a la epidemia de enfermedad generada por el virus SARS-CoV2(COVID-19). México: DOF, 2020 [citado mar 9, 2022]. Disponibleen: https://www.dof.gob.mx/nota_detalle.php?codigo=5590745&fecha=30/03/2020

  2. Institute for Global Health Sciences, University of California. La respuestade México al COVID-19: Estudio de caso. San Francisco, California:UCSF Institute for Global Health Sciences, 2020 [citado mar 9, 2022].Disponible en: https://www.globalhealthsciences.ucsf.edu/sites/globalhealthsciences.ucsf.edu/files/la_respuesta_de_mexico_al_covid_esp.pdf

  3. Villaseñor-Navarro Y, Sollozo-Dupont I. Daños colaterales de la pandemiapor Covid-19 en el tamizaje de cáncer de mama. Salud Publica Mex.2021;63(4):461. https://doi.org/10.21149/12525

  4. Benavides-Cobos G, Bolaños-Cacho CR, Gaitán-Díaz MG, Lagunes-Soto A, Velasco-Coello M, Zamora-Guzmán RI. Proposición con punto deacuerdo por el que se exhorta respetuosamente a la secretaría de saluda duplicar el número de mastógrafos en operación y de mastografíasrealizadas en todo el país. México: Senado de la República, 2021 [citadomar 9, 2022]. Disponible en: https://www.infosen.senado.gob.mx/sgsp/gaceta/65/1/2021-10-05-1/assets/documentos/18-PA_PVEM_cancer_de_mama_2021.pdf

  5. Fedewa SA, Cotter MM, Wehling KA, Wysocki K, Killewald R, MakaroffL. Changes in breast cancer screening rates among 32 community healthcenters during the COVID-19 pandemic. Cancer. 2021;127(23):4512-5.https://doi.org/10.1002/cncr.33859

  6. Breast Screening Working Group of the Covid-19, Cancer Global ModellingConsortium, Figueroa JD, Gray E, Pashayan N, Deandrea S, Karch A,et al. The impact of the Covid-19 pandemic on breast cancer early detectionand screening. Prev Med. 2021;151:106585. https://doi.org/10.1016/j.ypmed.2021.106585

  7. Vanni G, Pellicciaro M, Materazzo M, Bruno V, Oldani C, Pistolese CA, etal. Lockdown of breast cancer screening for COVID-19: possible scenario.In Vivo. 2020;34(5):3047-53. https://doi.org/10.21873/invivo.12139

  8. Anderson TJ, Lamb J, Donnan P, Alexander FE, Huggins A, Muir BB, et al.Comparative pathology of breast cancer in a randomised trial of screening.Br J Cancer. 2011;64:108-13. https://doi.org/10.1038/bjc.1991.251

  9. Epstein MM, Sundaresan D, Fair M, Garber L, Charpentier M, GurwitzJH, et al. Impact of COVID-19 on breast and prostate cancer screeningand early detection in a large health care provider group [abstract]. ClinCancer Res. 2020;26(supl 18):s11-03. https://doi.org/10.1158/1557-3265.COVID-19-S11-03

  10. Nickson C, Procopio P, Deij S, Velentzis L. COVID-19 scenario modellingfor cancer screening programs, the BreastScreen Australia Program.Australia: Cancer Council, 2020 [citado mar 9, 2022]. Disponible en:https://www.health.gov.au/sites/default/files/documents/2020/09/covid-19-scenario-modelling-for-cancer-screening-programs-the-breastscreenaustralia-program.pdf.

  11. Yong JHE, Mainprize JG, Yaffe MJ, Ruan Y, Poirier AE, Coldman A, et al.The impact of episodic screening interruption: COVID-19 and populationbasedcancer screening in Canada. J Med Screen. 2021;28(2):100-7. https://doi.org/10.1177/0969141320974711

  12. Kregting LM, Kaljouw S, de Jonge L, Jansen EEL, Peterse EFP, HeijnsdijkEAM, et al. Effects of cancer screening restart strategies after COVID-19disruption. Br J Cancer. 2021;124:1516-23. https://doi.org/10.1038/s41416-021-01261-9

  13. Duffy S, Vulkan D, Cuckle H, Parmar D, Sheikh S, Smith R, et al.Annual mammographic screening to reduce breast cancer mortalityin women from age 40 years: long-term follow-up of the UK Age RCT.Health Technol Assess. 2020;24(55):1-24. https://doi.org/10.3310/hta24550

  14. Uscanga-Sánchez S, Torres-Mejía G, Ángeles-Llerenas A, Domínguez-Malpica R, Lazcano-Ponce E. Indicadores del proceso de tamizaje decáncer de mama en México: un estudio de caso. Salud Publica Mex.2014;56(5):528-37.

  15. Centro Nacional de Excelencia Tecnológica en Salud. Inventario NacionalEMAT. México: Cenetec, 2016 [citado mar 9, 2022]. Disponible en: http://www.cenetec.salud.gob.mx/contenidos/biomedica/mapa.html

  16. Knaul FM, Arreola-Ornelas H, Velázquez E, Dorantes J, Méndez Ó,Ávila-Burgos L. El costo de la atención médica del cáncer mamario: el casodel Instituto Mexicano del Seguro Social. Salud Publica Mex. 2009;51(suppl2):S286-95. https://doi.org/10.1590/s0036-36342009000800019

  17. Instituto Mexicano del Seguro Social. A través de sus 10 clínicasde mama beneficia IMSS a 400 mil m ujeres anualmente. México: IMSS,2020 [citado mar 9, 2022]. Disponible en: http://www.imss.gob.mx/prensa/archivo/202010/686#:~:text=Ante%20la%20necesidad%20de%20contar,la%20doctora%20Silvia%20Mart%C3%ADnez%20S%C3%A1nchez

  18. National Cancer Institute. COVID-19 Resources. What people withcancer should know? Estados Unidos de Norte América. Estados Unidos:NCI, 2021 [citado mar 9, 2022]. Disponible en: https://www.cisnet.cancer.gov/publications/cancer-site.html#breast_header

  19. Schrag D, Hershman DL, Basch E. Oncology practice during the COVID-19 Pandemic. JAMA. 2020;323(20):2005-6. https://doi.org/10.1001/jama.2020.6236

  20. Velazquez AI, Hayward JH, Gregory B, Dixit N. Trends in breast cancerscreening in a safety-net hospital during the COVID-19 pandemic. JAMANetw Open. 2021;4(8):e2119929. https://doi.org/10.1001/jamanetworkopen.2021.19929

  21. Cancino RS, Su Z, Mesa R, Tomlinson GE, Wang J. The impact of COVID-19 on cancer screening: challenges and opportunities. JMIR Cancer.2020;6(2):e21697. https://doi.org/10.2196/21697




2020     |     www.medigraphic.com